Pushing boundaries, staying grounded, and having fun along the way are the key ingredients for success in biotech, writes ...

Raw authenticity can be disruptive in life sciences workplaces, but learning corporate fluency and stylistic pivots can help leaders become strategically authentic, writes Hope Mueller.

Life sciences organizations invest heavily in marketing visibility. Most maintain a website, actively use LinkedIn, and participate in industry events. These efforts signal credibility, momentum, and ...

Small and mid-cap biotechs face a fundamental strategic choice that will determine their survival in this new world of business. How will they compete against well-capitalized incumbents while ...

Today’s clinical trial landscape is defined by heightening competition for finite patient pools and increasingly narrow eligibility criteria. To overcome these hurdles, sponsors are moving away from ...

Ocular endpoints often introduce unique operational bottlenecks—such as referral delays and capacity limits—that can stall enrollment and compromise data integrity. This presentation features Jessica ...

Artificial intelligence is reshaping life sciences, but deciding whether to build or buy AI solutions can be complex. This guide explores the critical factors behind each approach, helping ...

The FDA has approved the first oral GLP-1 treatment for obesity in the U.S.—Novo Nordisk’s Wegovy pill. This once-daily medication represents a major advancement in weight management, offering an ...

The 2025 Regulatory-Industry Statistics Workshop (RISW) highlighted a pivotal shift toward integrating artificial intelligence with traditional statistical frameworks to streamline drug development.

Agentic AI is redefining how life sciences organizations approach discovery and operations. Unlike traditional AI models that simply predict outcomes, agentic systems act autonomously, making ...

On this episode of the Business of Biotech, Nick Manusos, CEO at Kenai Therapeutics, talks about his experiences building cell therapy spinouts from FujiFilm Cellular Dynamics, learning from big ...

Understanding the divergent regulatory standards between international markets is critical for therapy developers. Recent updates to European pharmaceutical legislation now redefine genome editing ...